
US Study: Nasal COVID Vaccine Shows Promise in Phase 1 Trial
Preliminary results from a Phase 1 clinical trial of a nasal vaccine developed by US-based startup Blue Lake Biotechnology have shown to reduce the risk of symptomatic COVID by 86% over three months when used as a booster dose....